Amgen (AMGN) Stock Up Since Jim Cramer Said “You Could Do a Lot Worse Than Amgen”

Published on March 30, 2026 at 7:06 am by Ramish Cheema in News

Amgen Inc. (NASDAQ:AMGN) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks.

Amgen Inc. (NASDAQ:AMGN) is one of the largest drug companies in the world. The firm is currently developing the weight loss drug MariTide. Its shares are up by 11.9% over the past year and are up by 24% since Cramer discussed the firm in June 2025 on Mad Money. They closed 7.5% higher on November 2025 after Amgen Inc. (NASDAQ:AMGN) released its earnings report for the fiscal third quarter. The results saw the firm post $9.6 billion in revenue and $5.64 in per share profit. Analysts, on the other hand, had expected Amgen Inc. (NASDAQ:AMGN) to post $8.98 billion in revenue and $5.04 in profit per share. 2026 has also been a good year for the shares as they are up by 6.5%. One notable movement occurred on February 4th when the stock closed 8% higher. On the 3rd, Amgen Inc. (NASDAQ:AMGN) had reported its fourth quarter earnings, which saw the firm post $9.9 billion in revenue and $5.29 in adjusted earnings per share to beat analyst estimates. Cramer was cautiously optimistic about the firm in his remarks:

“This is still a big biotech company with mid-single-digit earnings growth expected this year, not to mention potential upside for this GLP-1 drug down the road. But here’s the bottom line: We got plenty of data from this American Diabetes Association conference that ended earlier this week, and I think Amgen’s trial results were misunderstood. The stock did not deserve to get hit this hard. Lily’s still my favorite way to play the GLP-1 story. But if you’re looking for a bargain, you could do a lot worse than Amgen.”